BioNTech SE continued its clinical execution of the oncology strategy by focusing on two pan-tumor programs. Their bispecific antibody candidate, pumitamig, showed encouraging anti-tumor activity in a Phase 2 trial for extensive-stage small cell lung cancer. Plans to initiate pivotal trials for pumitamig in colorectal and gastric cancer were announced. Revenues for the third quarter of 2025 were €1.5 billion, with a net loss of €28.7 million. BioNTech strengthened its financial position with €16.7 billion in cash and received a $1.5 billion payment from Bristol Myers Squibb. Revenue guidance was increased to €2.6-2.8 billion, with lowered expense guidance for R&D, SG&A, and capital expenditures. The company reported progress in executing against its oncology strategy by advancing pan-tumor programs and collaborations with Bristol Myers Squibb. Financial results for the third quarter of 2025 showed increases in revenues compared to the previous year, driven by collaboration revenues. Research and development expenses were mainly driven by late-stage trials for immuno-oncology and antibody-drug conjugate programs. Sales, general, and administrative expenses decreased, mainly due to lower external costs. Net loss for the quarter was €28.7 million, compared to a net income of €198.1 million in the prior year. Basic and diluted loss per share were €0.12 for the quarter. Cash and cash equivalents plus security investments as of September 30, 2025, reached €16,704.9 million. The company’s revenue guidance for the full 2025 financial year was increased to €2.6-2.8 billion. Expense guidance for R&D, SG&A, and capital expenditures was lowered for the year. BioNTech plans to focus investments on R&D and scaling the business for late-stage development and commercial readiness in oncology while remaining cost-disciplined. They will continue to evaluate corporate development opportunities with the aim of driving sustainable growth and creating future value. The company launched a variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season in multiple regions. Financial results for the third quarter of 2025 included revenues of €1.5 billion, a net loss of €28.7 million, and basic and diluted loss per share of €0.12. BioNTech strengthened its financial position with €16.7 billion in cash and received a $1.5 billion payment from Bristol Myers Squibb. Revenue guidance was increased to €2.6-2.8 billion, with lowered expense guidance for R&D, SG&A, and capital expenditures. A conference call and webcast were scheduled for November 3, 2025, at 8:00 a.m. EST (2:00 p.m. CET). The company reported progress in executing its oncology strategy, advancing pan-tumor programs and collaborations. Financial results for the third quarter of 2025 showed increases in revenues compared to the previous year. Research and development expenses were mainly driven by late-stage trials for immuno-oncology and antibody-drug conjugate programs. Sales, general, and administrative expenses decreased, mainly due to lower external costs. Net loss for the quarter was €28.7 million, compared to a net income of €198.1 million in the prior year. Basic and diluted loss per share were €0.12 for the quarter. Cash and cash equivalents plus security investments as of September 30, 2025, reached €16,704.9 million. Shares outstanding as of September 30, 2025, were 240,455,450, excluding 8,096,750 shares held in treasury. The company received a $1.5 billion payment from its partnership with Bristol Myers Squibb, underscoring the strategic value of collaborations. Revenue guidance for the full 2025 financial year was increased to €2.6-2.8 billion, with lowered expense guidance for R&D, SG&A, and capital expenditures. BioNTech plans to focus investments on R&D and scaling the business for late-stage development and commercial readiness in oncology while remaining cost-disciplined. They will continue to evaluate corporate development opportunities with the aim of driving sustainable growth and creating future value. BioNTech increased its revenue guidance for the full 2025 financial year to €2.6-2.8 billion. Expense guidance for R&D, SG&A, and capital expenditures was lowered for the year. The company will focus investments on R&D and scaling the business for late-stage development in oncology while remaining cost-disciplined. The receipt of $1.5 billion from the partnership with Bristol Myers Squibb underscores the strategic value of collaborations in the long and short term. Revenue guidance for the full 2025 financial year was increased to €2.6-2.8 billion. Expense guidance for R&D, SG&A, and capital expenditures was lowered for the year. The company plans to focus investments on R&D and scaling the business for late-stage development in oncology while remaining cost-disciplined. The receipt of $1.5 billion from the partnership with Bristol Myers Squibb underscores the strategic value of collaborations in the long and short term. Revenue guidance for the full 2025 financial year was increased to €2.6-2.8 billion. Expense guidance for R&D, SG&A, and capital expenditures was lowered for the year. The company plans to focus investments on R&D and scaling the business for late-stage development in oncology while remaining cost-disciplined. The receipt of $1.5 billion from the partnership with Bristol Myers Squibb underscores the strategic value of collaborations in the long and short term. Revenue guidance for the full 2025 financial year was increased to €2.6-2.8 billion. Expense guidance for R&D, SG&A, and capital expenditures was lowered for the year. The company plans to focus investments on R&D and scaling the business for late-stage development in oncology while remaining cost-disciplined. BioNTech has increased its revenue guidance for the full 2025 financial year to €2.6-2.8 billion. With regards to COVID-19 vaccine franchise, the guidance reflects relatively stable pricing and market share compared to the previous year. The revenue guidance includes anticipated revenues from collaborations and service businesses. The financial guidance excludes external risks that are not yet known or quantifiable and may be subject to updates. BioNTech has lowered expense guidance for R&D, SG&A, and capital expenditures for the 2025 financial year. The company expects to focus investments on R&D and scaling the business for late-stage development in oncology while remaining cost-disciplined. Strategic capital allocation will continue to be a key driver of the company’s trajectory. The company may evaluate corporate development opportunities to drive sustainable long-term growth and create future value. BioNTech has lowered expense guidance ranges for R&D, SG&A, and capital expenditures for operating activities for the 2025 financial year. The company will focus investments on R&D and scaling the business for late-stage development and commercial readiness in oncology while remaining cost-disciplined. Strategic capital allocation will continue to drive the company’s trajectory. BioNTech’s strategy includes evaluating appropriate corporate development opportunities to drive sustainable long-term growth and create future value. The company has lowered expense guidance ranges for R&D, SG&A, and capital expenditures for operating activities for the 2025 financial year. The focus will be on R&D and scaling the business for late-stage development and commercial readiness in oncology while ensuring operational efficiency. Strategic capital allocation remains a key driver for the company’s trajectory. BioNTech has lowered expense guidance ranges for R&D, SG&A, and capital expenditures for operating activities for the 2025 financial year. Investments will be focused on R&D and scaling the business for late-stage development and commercial readiness in oncology, with a continued emphasis on cost optimization. The company may evaluate corporate development opportunities to drive sustainable long-term growth and create future value. In the third quarter of 2025, BioNTech and Pfizer launched a variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season in multiple regions. The vaccine was approved by regulatory authorities in the EU and US and began shipping to member states and healthcare facilities. BioNTech and Pfizer executed the commercial launch of a variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season. The vaccine was approved by regulatory authorities in the EU and US and began shipping to healthcare facilities. BioNTech and Pfizer executed the commercial launch of a variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season. The vaccine was approved by regulatory authorities in the EU and US and began shipping to healthcare facilities. In the third quarter of 2025, BioNTech and Pfizer executed the commercial launch of their variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season. The vaccine was approved by regulatory authorities in the EU and US and began shipping to healthcare facilities. In the third quarter of 2025, BioNTech and Pfizer launched a variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season in multiple regions. The vaccine was approved by regulatory authorities in the EU and US and began shipping to member states and healthcare facilities. In July, BioNTech and Pfizer’s LP.8.1-adapted monovalent COVID-19 vaccine was approved by the European Commission following a recommendation for marketing authorization by the EMA’s CHMP. Shipments of the vaccine began to EU member states that ordered this formulation. In August, the FDA approved the companies’ LP.8.1-adapted COVID-19 vaccine, with shipping starting immediately in the US. BioNTech and Pfizer launched a variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season, which was approved by regulatory authorities in the EU and US. Shipments began in multiple regions to ensure timely availability for the season. In July, BioNTech and Pfizer’s LP.8.1-adapted monovalent COVID-19 vaccine received approval from the European Commission after a positive recommendation from the EMA’s CHMP. Shipments to EU member states commenced following approval. In August, the FDA approved the LP.8.1-adapted COVID-19 vaccine for distribution in the US, ensuring timely availability for the vaccination season. BioNTech and Pfizer’s variant-adapted COVID-19 vaccine for the 2025/2026 season was approved by the European Commission in July. Shipments began to EU member states that ordered this formulation. In August, the FDA approved the vaccine for distribution in the US, ensuring availability for the upcoming vaccination season. BioNTech and Pfizer executed the commercial launch of a variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season. The vaccine was approved by the European Commission and the FDA, with shipments beginning in the EU and US. In August, the FDA approved the companies’ LP.8.1-adapted COVID-19 vaccine, with shipping starting immediately in the US. In August, the FDA approved the companies’ LP.8.1-adapted COVID-19 vaccine, with shipping starting immediately in the US. In August, the US FDA approved the LP.8.1-adapted COVID-19 vaccine, with immediate shipping to ensure availability for the vaccination season. BioNTech and Pfizer executed the commercial launch of a variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season. The vaccine was approved by the European Commission and the FDA, with shipments beginning in the EU and US. In August, the FDA approved the LP.8.1-adapted COVID-19 vaccine for distribution in the US, ensuring availability for the upcoming vaccination season. BioNTech and Pfizer executed the commercial launch of their variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season. The vaccine received approval from regulatory authorities in the EU and US, with shipments commencing to healthcare facilities. In September 2025, interim data from a global Phase 2 clinical trial evaluating pumitam

Read more at GlobeNewswire: BioNTech Announces Third Quarter 2025 Financial Results and